Core Viewpoint - The approval of the Anlailufu® trivalent influenza vaccine for infants aged 6-35 months expands its target population to include all individuals aged 6 months and older, enhancing immunization coverage against influenza [1] Group 1: Vaccine Approval and Target Population - The Anlailufu® trivalent influenza vaccine (0.5ml/dose) has received approval from the National Medical Products Administration (NMPA) to include infants aged 6-35 months, thus broadening its applicability to all individuals aged 6 months and above [1] - Anlailufu® is the first preservative-free trivalent influenza vaccine launched in China in 2006 [1] Group 2: Public Health Implications - Infants aged 6-35 months are considered a high-risk group for influenza-related complications, making vaccination a crucial and cost-effective preventive measure [1] - The recent approval of the four-valent and trivalent influenza vaccines by Sinovac within the same month allows for a unified vaccination approach for seasonal influenza for individuals aged 6 months and older, providing stronger immune protection for infants and other target populations [1] Group 3: Influenza Surveillance Data - According to the China CDC's report for the 42nd week of 2025, there were 49 reported outbreaks of influenza-like cases, a twelvefold increase from the previous week [1] - The predominant strain detected during the 2025-2026 influenza season is the H3N2 subtype of the influenza A virus [1] - Experts recommend promoting influenza vaccination, particularly among high-risk groups such as students, the elderly, and individuals with chronic diseases, to reduce the risk of infection and related severe cases and deaths [1]

Core Viewpoint - The approval of the quadrivalent influenza virus split vaccine by Beijing Kexing Biological Products Co., Ltd. for an expanded age range enhances the accessibility of high-quality influenza vaccines in China [1] Group 1 - The National Medical Products Administration (NMPA) approved the age expansion application for the quadrivalent influenza vaccine, now applicable to individuals aged 6 months and older [1] - The vaccine's new approval provides a unified dosage form for influenza prevention, offering a new choice for high-quality vaccination [1] - This development is expected to further improve the accessibility of influenza vaccination in China [1]